Decoy Therapeutics Named “R&D Solution of the Year” in 2026 BioTech Breakthrough Awards
Key Highlights
- ➤Decoy Therapeutics (DCOY) named “R&D Solution of the Year” by BioTech Breakthrough Awards
- ➤Optimized pan-coronavirus lead shows once-weekly dosing potential in preclinical studies
- ➤Decoy expects CTA or IND filing in second half of 2027 for Phase 1 trial
- ➤DCOY-CoV advances toward clinical development for high-risk respiratory-virus patients
Expert Statements
Rick Pierce, Chief Executive Officer of Decoy Therapeutics
“Recognition like this matters when it reflects real progress, and this year we’ve made a lot of it”
Rick Pierce, Chief Executive Officer of Decoy Therapeutics
“Our optimized lead has shown the potential for once-weekly dosing in preclinical studies, and we’re lining up the manufacturing and clinical partners to take it toward the clinic.”
Rick Pierce, Chief Executive Officer of Decoy Therapeutics
“It’s good to see independent reviewers recognize the R&D behind that work.”
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs), today announced it has been named “R&D Solution of the Year” in the sixth annual BioTech Breakthrough Awards program. BioTech Breakthrough is an independent market intelligence organization that recognizes standout life sciences and biotechnology companies, products and services around the world.
The recognition follows Decoy’s third quarter progress, in which its optimized pan-coronavirus lead showed once-weekly dosing potential in preclinical studies. Decoy expects to file a CTA or IND in the second half of 2027 to begin a Phase 1 trial.
Get started
Create a free account to read the full story.